



PCT/GB 00/02171

GB00/171



INVESTOR IN PEOPLE

4

**PRIORITY
DOCUMENT**
SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1(a) OR (b)

The Patent Office
Concept House
Cardiff Road
Newport
South Wales
NP10 8QQ

BET
7.2402
#7/ Priority
Doc

REC'D 25 JUL 2000

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

PCT

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.

Signed

AmBrewster

Dated 12 July 2000

This Page Blank (uspto)

This Page Blank (uspto)

04 JUN 1999

04 JUN 1999

1/77

Patents Act 1977

RECEIVED BY POST

Patent
Office04JUN99 E451803-1 C00446
P01/7700 0.00 - 9912877.9

Request for Grant of a Patent

The Patent Office
Cardiff Road
NEWPORT NP9 1RH

1. Your reference P79666

2. Patent Application number
(the Patent Office will fill in this part)

9912877.9

3. Full name, address and postcode of the or
of each Applicant (*underline all surnames*)SLS Biophile Limited
Units 1 & 2, Heol Rhosyn
Dafen Industrial Park
Llanelli
Carmarthenshire SA14 8QGPatent Office ADP Number (*if you know it*)If the applicant is a corporate body, give
the country/state of its incorporation

United Kingdom

7165229001

4. Title of the Invention

Tissue Rejuvenation

5. Name of your Agent (*if you have one*)

URQUHART-DYKES & LORD

"Address for Service" in the United Kingdom to
which all correspondence should be sent
(*including the postcode*)Alexandra House
1 Alexandra Road
SWANSEA
SA1 5ED
United KingdomPatents ADP Number (*if you know it*)

1644005

6. If you are declaring priority from one or more
earlier Patent Applications, give the country
and the date of filing of the or of each of these
earlier Applications and (*if you know it*) the or each

Country

Priority application No.
(*if you know it*)Date of Filing
(*Day/month/year*)7. If this Application is divided or otherwise derived
from an earlier UK Application, give the Number
and the Filing Date of the earlier Application

Number of earlier application

Date of Filing
(*Day/month/year*)8. Is a Statement of Inventorship and of Right to
Grant of a Patent required in support of this
request ?

Yes

(Answer 'Yes' if:

- a) any Applicant named in part 3 is not an inventor, or
- b) there is an inventor who is not named as an Applicant, or
- c) any named Applicant is a corporate body.)

9. Enter the number of sheets for any of the following items you are filing with this

Form. Do not count copies of the same document

Continuation sheet of this Form	0
Description	7
Claim(s)	0
Abstract	0
Drawing(s)	2

10. If you are also filing any of the following state how many against each item

Priority documents	0
Translations of priority documents	0
Statement of Inventorship and Right to Grant a Patent (<i>Patents Form 7/77</i>)	0
Request for Preliminary Examination (<i>Patents Form 9/77</i>)	0
Request for Substantive Examination (<i>Patents Form 10/77</i>)	0
Any other documents (<i>please specify</i>)	0

11. I/We request the grant of a Patent on the basis of this Application

Signature

Date

URQUHART-DYKES & LORD

3 June 1999

12. Name and daytime telephone number of person to contact in the United Kingdom

Mr G M Davies
01792 474327

Warning

After an Application for a Patent has been filed, the Comptroller of the Patent Office will consider whether Publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a Patent abroad without first getting written from the Patent Office unless an Application has been filed at least 6 weeks beforehand in the United Kingdom for a Patent for the same invention and either no direction prohibiting Publication or communication has been given, or any such direction has been revoked.

Tissue Rejuvenation

5 The present invention relates to tissue rejuvenation and in particular to tissue rejuvenation by means of selective production of collagen at a target site.

10 The human body has a variety of different types of collagen, which essentially constitute the extracellular matrix of the body. This matrix is the material that binds and supports cells and is essential for the survival of a multicellular organism. Collagens provide the tissue with tensile strength.

15 The various collagen containing structures in the body include bone, dentin, cartilage, uterus and the larger vessels in the circulatory system. As the body ages the rate of collagen naturally decreases leading to breakdown in tissue and organ structure and function. Other problems can also exacerbate or cause tissue or organ structure deterioration due to inhibition of collagen formation.

20 According to a first aspect, the invention comprises a technique for stimulating collagen containing structures, the technique comprising illuminating a target structure with illuminating radiation causing elevation of the temperature of a target structure, the radiation dosed to the target being controlled to induce an inflammatory response in the target tissue.

30 The absorption of the radiation by the target structure at

the predetermined low level controlled dose (resulting in the inflammatory response of the target structure tissue) stimulates collagen regrowth.

5 It is important that the radiation dose is controlled to ensure that overheating of the target tissue structure does not take place. Overheating tending to injure the tissue by passing beyond the inflammatory phase to the proliferate and/or remodelling phase does not result in
10 optimum collagen formation. It is important therefore that the radiation energy dose delivered is of sufficiently low intensity and power to avoid tissue destruction. The radiation dose is therefore controlled dependent upon the body structure or tissue being
15 illuminated but in all cases the intensity and duration of the illuminating radiation is relatively low level to prevent damage of the target structure or tissue.

The wavelength of the illuminating radiation is selected
20 such that there is at least some absorption by the target structure or tissue.

In a preferred embodiment the radiation delivered is electromagnetic energy, preferably light, desirably
25 substantially in the bandwidth 400-1500nm (more preferably substantially in the bandwidth 500-1000nm).

The illuminating radiation may be generated by laser, laser diode, light emitting diode, or a broad band white
30 light source. The illuminating radiation is preferably of a discrete wavelength or relatively narrow wavelength

bandwidth. For a broad band white light source an appropriate filter is preferably provided.

Where the illuminating radiation is laser radiation, the laser may, for example comprises pulsed dye laser (585nm), an Argon Ion laser (514nm), Ti:Sapphire laser (400nm-1100nm), Ruby laser (694nm), Nd:YAG laser (1064nm), or Frequency Doubled Nd:YAG laser (532nm).

a suitable laser diode would be a Gallium Arsenide laser diode at 630-690nm or 790-980nm.

LED's at wavelengths substantially in the range 550-1000nm would be suitable.

The technique can be used on a variety of body tissue structures either by means of direct external illumination of structures or by means of directing the illuminating radiation into the body (for example along a suitable waveguide) to be delivered to the site of the internal target structure.

According to a second aspect, there is provided apparatus for use in effecting refurbishment of tissue and/or tissue structures, which apparatus includes:

- i) a source of illuminating radiation; and,
- ii) means for directing the illuminating radiation to a target site.

The means for directing the illuminating radiation to the target site preferably includes focussing means (for example optical focussing means). The means for directing the illuminating radiation to the target site preferably includes a flexible optical line including a distal portion through which the radiation is emitted in order to illuminate the target structure. The optical line may comprise an optical waveguide such as a length of fibreoptic tube.

The means for directing the illuminating radiation to the target site is preferably configured to permit manual manipulation enabling the zone of radiation impingement with the target site to be manually altered. Alternatively, the apparatus may be provided with an automated drive arrangement.

Desirably, the illuminating radiation is pulsed, preferably having a pulse duration substantially in the range 1 microsecond-100ms.

The invention will now be further described in specific embodiments by way of example only, and with reference to the accompanying drawings, in which:

Figure 1 is a schematic representation of a first embodiment of a technique according to the invention,

Figure 2 is a schematic representation of a second embodiment of a technique according to the invention;

Figure 3 is a schematic representation of a further embodiment of a technique according to the invention;

5 Figure 4 is a schematic representation of a further embodiment of a technique according to the invention;

Figure 5 is a schematic representation of a further embodiment of a technique according to the invention; and,

10

Figure 6 is a schematic representation of a further embodiment of a technique according to the invention.

Referring to the drawings, and initially to Figure 1,
15 there is shown a tissue rejuvenation technique in which an arrangement 1 includes a light source 2, such as an LED, laser diode or other laser or a white light source (provided with an appropriate filter), having a wavelength in a narrow bandwidth in the range 550-1000nm, directs a
20 beam 3 via focussing optics 4 into a fibreoptic waveguide 5. Light emitted from the distal end of fibreoptic waveguide 5 passes through a collimating lens 6 where it is directed to illuminate the surface of a tissue structure 7.

25

In the embodiment shown in Figure 2, the beam 3 emitted from light source 2 passes directly through a focussing lens 16 which focusses the beam onto the tissue structure 7.

30

In the embodiment shown in Figure 3, the beam 3 from the

light source 2 is directed to a scanning optical arrangement comprising rotating scanning mirrors 9, 10 arranged to scan the beam in orthogonal X-Y directions onto the tissue 7.

5

In each of the embodiments shown in Figures 1 to 3, the relevant tissue structure 7 is directly illuminated from externally of the body (extra-corporeal illumination).

10

The intensity and duration of the light beam illuminating the tissue 7 is controlled such that the energy dosed to the tissue is at a level where collagen formation is promoted, without the tissue being "injured" to a degree at which structural integrity of the tissue deteriorates.

15

Illumination promoting collagen production mirroring wound healing in the inflammatory, proliferate and remodelling phases results in collagen production and enhancement of the structural integrity of the tissue.

20

It is important that the wavelength of the light illuminating the tissue is selected to have at least a component which is selectively absorbed to the required degree by the tissue in question. Appropriate selection of the wavelength to be absorbed by the tissue, or a chromophore at or below the tissue surface, can enable discrete target sites at or below the tissue surface to be targeted.

25

30

The arrangements shown in Figure 4 to 6 relate to interstitial rejuvenation techniques where an extra corporeal light source 2 produces a beam 3 which can be

directed across the body surface interface to target an internal cell structure 11, 12.

5 In the embodiment shown in Figure 4, the light beam 3 is focussed into a fibreoptic waveguide 5 which extends through a sheathing catheter 13. Light emanating from the end of fibreoptic waveguide 5 illuminates the target structure 11 below the body surface 14.

10 In the embodiments shown in Figures 5 and 6, the fibreoptic waveguide 5 extends into and along a target vessel 12 which comprises the circulatory system of the body (such as for example an artery).

15 In the embodiment of Figure 5, light is reflected from a mirror end 15 to illuminate the desired "target" portion of the internal vessel wall 12.

20 In the embodiment shown in Figure 6, the fibreoptic waveguide 5 is provided with a diffusing end 16 arranged to diffuse the light to illuminate radially the entire "target" portion of the vessel wall 12.

25 Illumination of the relevant tissue target structure with illuminating radiation of the required wavelength and dosage produces the inflammatory/wound healing response promoting the maximum degree of collagen formation. Promotion of collagen at the target site effectively rejuvenates the target tissue/structure.

This Page Blank (uspto)

TISSUE REJUVENATION

①

DIRECT ILLUMINATION

FIG 1






FIG 2



SCANNING SYSTEM..


FIG 3



This Page Blank (uspto)

INTERSTITIAL ILLUMINATION VIA FIBRE OPTIC

2



FOR USE IN VEINS | ARTERIES

AS ABOVE

FIG 5





FIG 6



PCT/GB00/02171.

57.00

UDL

This Page Blank (uspto,